Pharmaceuticals News and Research

RSS

PDI receives new contract sales engagement; expects $10 to $12 million revenue in 2010

PDI, Inc., a leading provider of sales and marketing support to U.S. health care companies, has been awarded a new contract sales engagement with a Top 10 pharmaceutical company that is expected to generate approximately $10 to $12 million in revenue in 2010.

12 Jan 2010

Proteus Biomedical signs worldwide license and collaboration agreement with Novartis

Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus’ novel sensor-based technologies in the field of organ transplantation.

12 Jan 2010

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene® I.V. (nicardipine hydrochloride) is significantly more effective than intravenous labetalol for the management of blood pressure (BP) in stroke patients.

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

NicOx S.A. today announced that NicOx and TOPIGEN Pharmaceuticals Inc. have mutually terminated their collaboration for TPI 1020. This decision was made as a result of the acquisition of TOPIGEN by Pharmaxis announced yesterday.

12 Jan 2010

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

Isis Pharmaceuticals, Inc. announced today that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. ISIS-APOCIIIRx provides a novel approach to treat hypertriglyceridemia, or high levels of triglycerides (TG).

12 Jan 2010

DSG teams up with pharmaceutical technology company to speed early detection of major diseases

DSG, a leader in electronic data capture (EDC) has teamed up with a leading-edge pharmaceutical technology company to speed the early detection of Alzheimer’s, Parkinson’s, and Diabetes.

12 Jan 2010

AHF to host protest targeting Merck over the steep price for its key HIV/AIDS drug, Isentress

AIDS Healthcare Foundation (AHF) will host a protest Tuesday, January 12, at 10:30am targeting Merck and Co. Pharmaceuticals over the steep price for its key HIV/AIDS drug, Isentress, during the 28th Annual J.P. Morgan Healthcare Conference in San Francisco.

12 Jan 2010

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Paragon Biomedical, Inc. announced today that it has launched the second phase of its restructuring and growth plan for worldwide operations. Gena Reed, Paragon's Founder and Chief Executive Officer, said the strategy will build upon the company's strengths in its key therapeutic areas and regions.

12 Jan 2010

Idenix Pharmaceuticals announces significant progress in HCV development programs

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced significant progress in three HCV programs

12 Jan 2010

Pharmaron Holdings acquires Bridge Laboratories China

Pharmaron Holdings Limited, today announced it completed the acquisition of Bridge Laboratories China. Bridge Laboratories China is the leading contract research organization (CRO) in China providing western standard GLP-compliant toxicology services to pharmaceutical and biotech companies from around the world. With this acquisition, Pharmaron becomes the first integrated CRO in China supporting clients with drug discovery and development processes in support of IND filings. This strategic acquisition strengthens Pharmaron's leading position in the fast-growing, highly dynamic pharmaceutical CRO industry.

12 Jan 2010

Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA

MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.

12 Jan 2010

ARCA biopharma to receive US patent for methods of heart failure treatment with genetic testing based bucindolol

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its U.S. Patent Application Number 11/226,908 entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting.” The Notice of Allowance is the USPTO’s official communication that the examination of the patent application has been successfully completed and that a patent will be issued.

12 Jan 2010

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has submitted an investigational new drug (IND) amendment to the United States Food and Drug Administration (FDA) which includes the design of a proposed Phase 3 clinical trial of Neoprobe’s RIGScan® CR radiopharmaceutical.

12 Jan 2010

KV Pharmaceutical, Hologic amend Gestiva asset purchase agreement

KV Pharmaceutical Company ( KVa/KVb) today announced it has entered into an amendment to the existing asset purchase agreement with Hologic, Inc. to secure the full U.S. and worldwide rights to Gestiva(TM), subject to the terms and conditions set forth in the amendment. Upon approval by the U.S. Food and Drug Administration (the "FDA"), Gestiva(TM) will be the first and only FDA-approved treatment for the prevention of preterm birth in women who are pregnant with a single baby and have spontaneously delivered a single baby preterm in the past.

From Hologic, Inc. 12 Jan 2010

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Trubion Pharmaceuticals, Inc. today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus (SLE).

12 Jan 2010

AmerisourceBergen announces new programs for long term care and retail pharmacies

AmerisourceBergen, under its’ PRxO® Generics Solution, today announced a new program for long term care pharmacies and an expanded program for retail pharmacies. The new solutions are tailored to better meet customer needs as generic prescription demands continue to increase.

12 Jan 2010

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

Antares Pharma, Inc. and the Population Council today announced successful results from a dose-finding Phase 2 trial for a novel contraceptive gel containing the progestin Nestorone and estradiol (NES/E2) utilizing the Antares ATD (advanced transdermal delivery) gel system. Based on this successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialize this novel contraceptive gel.

12 Jan 2010

BioCryst Pharmaceuticals signs agreements with two additional partners

BioCryst Pharmaceuticals, Inc. today announced that it has signed agreements with two additional partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities for territories outside of the U.S. BioCryst's new partners are Merck Serono for Europe, Russia, Canada and Singapore and Hikma Pharmaceuticals PLC for the Middle East and North Africa (MENA) region, excluding Israel.

12 Jan 2010

Medical Care Technologies reaches definitive agreement to acquire GUC's technologies

Medical Care Technologies Inc. today announced that it has reached a definitive agreement to acquire various technologies from Great Union Corporation, ("GUC") a private Hong Kong corporation.

12 Jan 2010

Pharmaceuticals News and Research

PDI receives new contract sales engagement; expects $10 to $12 million revenue in 2010

Proteus Biomedical signs worldwide license and collaboration agreement with Novartis

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

Millipore introduces new Viresolve Pro+ Solution

NicOx, TOPIGEN Pharmaceuticals terminate TPI 1020 collaboration

Isis Pharmaceuticals adds ISIS-APOCIIIRx to its development pipeline to treat TG

DSG teams up with pharmaceutical technology company to speed early detection of major diseases

AHF to host protest targeting Merck over the steep price for its key HIV/AIDS drug, Isentress

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Idenix Pharmaceuticals announces significant progress in HCV development programs

Pharmaron Holdings acquires Bridge Laboratories China

Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA

ARCA biopharma to receive US patent for methods of heart failure treatment with genetic testing based bucindolol

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

KV Pharmaceutical, Hologic amend Gestiva asset purchase agreement

Pfizer commences SBI-087 Phase 2 clinical trial for RA

AmerisourceBergen announces new programs for long term care and retail pharmacies

Antares Pharma, Population Council report positive Phase 2 results for novel NES/E2 contraceptive gel

BioCryst Pharmaceuticals signs agreements with two additional partners

Medical Care Technologies reaches definitive agreement to acquire GUC's technologies

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence